FDA to review efficacy issues in morning-after pill

Share this article:

HRA Pharma, a French drug manufacturer, says that its levonorgestrel-based emergency contraceptive, Norlevo,  loses efficacy in women who weigh over 165 pounds, and is ineffective in women who weigh over 176 pounds. The drugmaker requested permission to update its label from EU regulators.

FDA, responding to a query from Reuters on Monday, said they are "currently reviewing the available and related scientific information on this issue, including the publication upon which the Norlevo labeling change was based," and that "the agency will then determine what, if any, labeling changes to approved emergency contraceptives are warranted."

A spokeswomen for HRA Pharma told Mother Jones that upping the dosage does not solve the problem.

Plan B, sold by Teva Pharmaceuticals, and generic versions thereof, are also levonorgestrel-based emergency contraceptives.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.